指甲银屑病医师整体评估(PGA-F)的研发与验证
本研究研发并验证了用于评估指甲银屑病严重程度的医师整体评估量表PGA-F。通过文献回顾、概念引出、认知访谈和专家咨询构建量表,并对皮肤科医生和临床试验研究者进行评分者间信度测试。结果显示PGA-F具有内容效度、良好的评分者间信度和与mNAPSI的充分相关性,适用于临床和研究。
要点
- PGA-F将指甲银屑病严重程度分为5级(清除至重度)。
- PGA-F与mNAPSI在基线和第26周有充分相关性(>0.30)。
- 皮肤科医生和临床试验研究者的评分者信度分别为0.85和0.73。
核心结论
- PGA-F是一种快速、有效且可靠的临床医生评定量表,可用于临床实践和研究。
研究设计与样本
- 通过文献回顾、概念引出、试点认知访谈和临床专家咨询开发PGA-F。
- 采用多阶段混合方法分析,包括10名执业皮肤科医生的认知访谈。
- 使用多面Rasch分析测试22名皮肤科医生和8名临床试验研究者的评分者间信度。
- 在筛选和基线时评估PGA-F与mNAPSI的并发效度和区分度。
主要发现
- PGA-F综合多个疾病特征的严重程度评级,将患者分为5个等级(清除至重度)。
- 认知访谈证实内容效度:所有10名(100%)参与者同意临床标准与指甲银屑病一致;无严重程度分级不匹配;训练照片为真实表现。
- 所有PGA-F条目局部独立,针对严重程度连续体上的患者具有互补精度(条目拟合统计量<1.5可接受阈值;皮肤科医生精确一致率44%,试验研究者61.5%,均超过40%可接受阈值)。
- 临床医生信度超过可接受阈值:皮肤科医生0.85,临床试验研究者0.73。
- mNAPSI与PGA-F在基线和第26周有充分相关性(>0.30),严重程度区分显著,且PGA-F每个分类严重程度等级的mNAPSI呈单调递增。
关键数值与推荐
- PGA-F分为5个等级:清除至重度。
- 条目拟合统计量<1.5为可接受阈值。
- 精确一致率可接受阈值>40%。
- 临床医生信度可接受阈值:皮肤科医生0.85,临床试验研究者0.73。
- mNAPSI与PGA-F相关性>0.30为充分。
临床怎么用
- PGA-F可用于临床实践中快速评估指甲银屑病严重程度。
- PGA-F也可用于临床研究中的疗效评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Several clinician-rated scoring systems are available to assess nail psoriasis severity, but only one has been partially validated. OBJECTIVE: To develop and validate the Physician's Global Assessment of Fingernail Psoriasis (PGA-F), a new clinician-rated severity scale. METHODS: A literature review, concept elicitation, pilot cognitive debriefing and clinical expert consultations informed the development of the PGA-F. A multistage mixed-methods analysis consisted of practising dermatologist cognitive interviews (n = 10) for instrument clarity, relevance and comprehensiveness. Inter-rater reliability (IRR) of ratings from dermatologists (n = 22) and clinical trial investigators (n = 8) was tested using many-facet Rasch analysis. Concurrent validity between the PGA-F and modified Nail Psoriasis Severity Index (mNAPSI) at screening and baseline was assessed along with the degree of discrimination. Intraclass correlation coefficient (ICC) for single raters at multiple assessments determined IRR. RESULTS: The PGA-F synthesizes severity ratings across multiple disease features that classify individuals into 1 of 5 levels (clear to severe). Cognitive interviews confirmed content validity: all (n = 10, 100%) participants who agreed clinical criteria were consistent with nail psoriasis; no mismatched severity levels; and training photographs were realistic representations. All PGA-F items were locally independent and targeted patients along the severity continuum with complementary precision (item fit statistics: < the 1.5 acceptability threshold; exact agreements among the dermatologists [44%] and trial investigators [61.5%] exceeded 40% of acceptability threshold). Clinician reliability exceeded the threshold of acceptability for dermatologists and clinical trial investigators: 0.85 and 0.73, respectively. There was adequate correlation (>0.30) between mNAPSI and PGA-F at baseline and Week 26 with significant discrimination of severity and monotonic increases in the mNAPSI for each level of categorical severity on the PGA-F. ICC results for each type of IRR indicate that clinicians were consistent in individual patient ratings. CONCLUSION: The PGA-F is a rapid, valid and reliable clinician-rated severity scale for use in clinical practice and research.
引用
- Hudgens S, Rich P, Geng Z, et al. Development and validation of the Physician's Global Assessment of Fingernail Psoriasis. J Eur Acad Dermatol Venereol. 2021. PMID: 34014011. doi:10.1111/jdv.17387
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。